Circassia’s pipeline of immunotherapies is based on its unique ToleroMune® technology, and with strong support from its shareholders the Company has made significant progress developing its products following its establishment in 2006. As a private company, we expanded our portfolio of treatments, raised a total of £105 million in investment and successfully completed numerous clinical studies. This progress culminated in a successful initial public offering on the London Stock Exchange on 18 March 2014, and to date the Company has raised over £300 million in investment. We also continue to maintain strong links with allergy experts, and our joint venture with McMaster University (Hamilton, Canada), Adiga Life Sciences Inc, is pursuing promising new science in the field.
Circassia’s ultimate ambition is to build a successful financially self-sustaining specialty biopharma company, focused on improving patients’ lives around the world. In the short term, we plan to complete the development and launch of our first allergy treatment, Cat-SPIRE. To achieve this, we are building our commercial capabilities and advancing our phase III program. With the support of our investors, Circassia is making good progress towards meeting its long-term goal.[/td_text_with_title]
Study on track to report in H1 2016 1,409 subjects randomised; 19% above target Oxford, UK – 8 January 2015: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty biopharmaceutical company focused on allergy, today announces that it has completed recruitment into the pivotal phase III study of its cat allergy treatment, Cat-SPIRE. […]